CRSP
HEALTHCARECrispr Therapeutics AG
AI Insight
What's Moving CRSP Today?
No stock-specific AI insight has been generated for CRSP yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$44.12$78.48
$54.37
Fundamentals
Market Cap$5.5B
P/E Ratio—
EPS$-6.17
Dividend Yield—
Dividend / Share—
ROE-31.2%
Profit Margin—
Debt / Equity—
Trading
Volume285K
Avg Volume (10D)—
Shares Outstanding98.5M
CRSP News
31 articles- Why CRISPR Therapeutics Stock Has Been on a Roller-Coaster Ride This YearMotley Fool·Jun 18, 2026
- CRISPR Therapeutics AG (CRSP) Ascends While Market Falls: Some Facts to NoteYahoo Finance·Jun 17, 2026
- The Best Biotech Stocks to Buy in 2026Motley Fool·Jun 17, 2026
- Is CRISPR Therapeutics’ (CRSP) ESOP Shelf Registration Quietly Redefining Its Long‑Term Risk‑Reward Profile?Simply Wall Street·Jun 17, 2026
- Moderna (MRNA) Surges 6.3%: Is This an Indication of Further Gains?Yahoo Finance·Jun 17, 2026
- CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should KnowYahoo Finance·Jun 16, 2026
- CRISPR Therapeutics Expands Funding Capacity As Gene Editing Pipeline AdvancesYahoo Finance·Jun 13, 2026
- CRISPR Therapeutics AG (CRSP) Advances But Underperforms Market: Key FactsYahoo Finance·Jun 11, 2026
- CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to KnowYahoo Finance·Jun 10, 2026
- [Form 4] CRISPR Therapeutics AG Insider Trading ActivityStock Titan·Jun 10, 2026
- CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus?Motley Fool·Jun 8, 2026
- CRISPR Therapeutics AG (CRSP): One of The most Shorted Mid Cap Stocks to Buy on Robust Gene Editing PipelineYahoo Finance·Jun 6, 2026
- Eli Lilly Pressure And RNA Expansion Reframe CRISPR Therapeutics OutlookYahoo Finance·Jun 5, 2026
- CRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside PotentialMotley Fool·Jun 3, 2026
- Why Is CRISPR Therapeutics (CRSP) Down 0.7% Since Last Earnings Report?Yahoo Finance·Jun 3, 2026
- [Latest] Global CRISPR-based Gene Editing Market Size/Share Worth USD 12.6 Billion by 2034 at a 13.01% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)Yahoo Finance·Jun 3, 2026
- Eli Lilly Just Proved Gene Editing Could Be Pharma's Next Gold Rush -- but CRISPR Therapeutics Investors Should Watch OutMotley Fool·Jun 3, 2026
- 3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026Yahoo Finance·Jun 2, 2026
- CRISPR Therapeutics (CRSP) CMO nets shares after mandated RSU tax saleStock Titan·Jun 1, 2026
- CRISPR Therapeutics' Secret Weapon That Many Investors Are OverlookingMotley Fool·Jun 1, 2026
- Vertex Stock Down Nearly 8% in 3 Months: Time to Buy or Stay Cautious?Yahoo Finance·Jun 1, 2026
- CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on ItYahoo Finance·Jun 1, 2026
- CRISPR Therapeutics Conferences May Reframe Valuation Gap And Growth OutlookYahoo Finance·Jun 1, 2026
- CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?The Motley Fool·May 31, 2026
- Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics?The Motley Fool·May 26, 2026
- Nwam LLC Has $3.38 Million Position in CRISPR Therapeutics AG $CRSPMarketBeat·May 10, 2026
- Is This Millionaire-Maker Biotech Stock a Buy Right Now?The Motley Fool·May 6, 2026
- CRISPR Therapeutics Has Major Catalysts Ahead. Is This Biotech Stock a Screaming Buy?The Motley Fool·Apr 21, 2026
- 2 Billion Reasons to Love CRISPR Therapeutics Right NowThe Motley Fool·Apr 13, 2026
- This Biotech Has a Pipeline That Could Redefine Its Entire Therapeutic AreaThe Motley Fool·Apr 8, 2026
- Anti-Aging Protein Research Takes a Step Forward with Cell CloningBenzinga·Mar 24, 2026
All 31 articles loaded
Price Data
Open$54.15
Previous Close$53.99
Day High$55.48
Day Low$53.66
52 Week High$78.48
52 Week Low$44.12
52-Week Range
$44.12$78.48
$54.37
Fundamentals
Market Cap$5.5B
P/E Ratio—
EPS$-6.17
Dividend Yield—
Dividend / Share—
ROE-31.2%
Profit Margin—
Debt / Equity—
Trading
Volume285K
Avg Volume (10D)—
Shares Outstanding98.5M
About Crispr Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on the development of gene-based transformative drugs for serious human diseases. The company is headquartered in Zug, Switzerland.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—